Form 4: Lilly Endowment Sells $161M Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reported the sale of 192,961 shares of common stock for approximately $161 million on October 3, 2025, under a 10b5-1 plan.

Summary

• Lilly Endowment Inc., identified as a 10% owner of Eli Lilly & Co (LLY), reported transactions on October 3, 2025.
• The reporting person disposed of a total of 192,961 shares of Eli Lilly & Co common stock.
• These sales were executed at weighted average prices ranging from $821.418 to $847.601 per share, with individual transaction prices ranging from $821.00 to $847.63.
• The total value of the shares sold is approximately $161,000,000.
• Following these transactions, Lilly Endowment Inc. directly beneficially owns 94,836,978 shares of common stock.
• The transactions were made pursuant to a contract, instruction, or written plan for the sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of an insider stock sale, likely pre-planned under a 10b5-1 plan, and does not inherently reflect positively or negatively on the company's operational performance or future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports an insider transaction by a significant shareholder and does not provide direct insights into broader industry trends or competitive landscape. It is a routine disclosure of a pre-planned stock sale.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, sold 192,961 shares of common stock. Transactions by a 10% owner are considered related party transactions.

Stakeholder Impact

• Shareholders: May observe a significant owner reducing their stake, though the 10b5-1 plan suggests a pre-scheduled, non-discretionary sale, which typically mitigates concerns about negative signals regarding the company's future.

Key Dates

Recommendation

The filing reports a significant sale of shares by a 10% owner under a pre-arranged 10b5-1 plan. This type of transaction is typically for diversification or liquidity purposes and does not inherently signal a change in the company's fundamental outlook or performance. Therefore, it does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

Eli Lilly, LLY, Lilly Endowment, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, Pharmaceutical, Healthcare